Apollo Endosurgery
Apollo Endosurgery, Inc. is an Austin-based medical device company developing minimally invasive endoscopic systems - OverStitch (suturing) and Orbera (intragastric balloon) - that enable incisionless weight-loss procedures (ESG, TORe) for adult patients with obesity, distributed to hospitals and specialty clinics and now operating within Boston Scientific's Endura brand.
- Company typePrivate
- Founded2006
- HeadquartersAustin, United States
- Headcount101–250
- GTM typeB2B
- OfferingHardware or Manufacturing
What Apollo Endosurgery does
Apollo Endosurgery, Inc. was a publicly traded medical device company headquartered in Austin, Texas, founded in 2006 and operating under NASDAQ: APEN prior to its acquisition by Boston Scientific Corporation in April 2023 for $615 million. The company developed minimally invasive endoscopic devices for gastrointestinal weight-loss procedures, with two core platforms: the OverStitch Endoscopic Suturing System (including the next-generation OverStitch NXT) that enables full-thickness internal suturing through the mouth without incisions, supporting Endoscopic Sleeve Gastroplasty (ESG) and Transoral Outlet Reduction (TORe) procedures; and the ORBERA Intragastric Balloon System, a temporary balloon implant placed for up to six months to create satiety. Indicated for adult patients with obesity (BMI 30-50 for OverStitch/ESG; 30-40 for Orbera), the products address patients who failed supervised weight-control programs or who regained weight after gastric bypass. Regulatory positioning was anchored by FDA de novo clearances for endoscopic bariatric systems, establishing first-in-class authorization for the incisionless approach.
The company sold capital equipment (OverStitch) and disposable/implantable components (Orbera, suturing reloads) to hospitals, ambulatory surgical centers, and specialty clinics through an enterprise field sales motion targeting gastroenterologists and bariatric surgeons. Revenue was therefore hardware-led with consumable-driven recurring use per procedure, supplemented by patient demand generation via the Find a Doctor locator and education resources now housed under Boston Scientific's Endura Weight Loss Solutions brand. Distribution historically relied on Apollo's direct sales force; the April 2023 Boston Scientific acquisition extended reach through BSX's global enterprise network and integrated the Apollo portfolio into BSX's endoluminal surgery franchise, alongside complementary diagnostics such as the 2016 LPATH acquisition and prior capital raises totaling over $300M of equity and debt from investors including Innovatus Capital Partners, PTV Healthcare Capital, H.I.G. Capital, and Novo Holdings.
Apollo Endosurgery firmographics
Firmographics- Name
- Apollo Endosurgery
- Legal name
- Apollo Endosurgery, Inc.
- Website
- https://apolloendo.com
- Company type
- Private
- Founded year
- 2006
- Operating status
- Acquired
- Headcount range
- 101–250 employees
- Short description
- Apollo Endosurgery, Inc. is an Austin-based medical device company developing minimally invasive endoscopic systems - OverStitch (suturing) and Orbera (intragastric balloon) - that enable incisionless weight-loss procedures (ESG, TORe) for adult patients with obesity, distributed to hospitals and specialty clinics and now operating within Boston Scientific's Endura brand.
- Ownership category
- akta.pro rank
Apollo Endosurgery industry classification
Industry- Product category
- Endoscopic Bariatric Medical Devices
- NAICS
- Surgical and Medical Instrument Manufacturing (339112)
- SIC
- Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Endoscopy Systems & Accessories (Scopes, Cameras, Light Sources, Insufflation) (HLAHADAB)
- akta.pro secondary industries
- Endoscopic Therapeutic & Access Devices (Trocars, dilators, biopsy/ablation tools) (HLAHADAN), Advanced Endoscopy (ERCP/EUS/Interventional) (HLAKAEAC)
Keywords
Where Apollo Endosurgery is headquartered
LocationHeadquarters
- HQ city
- Austin
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Apollo Endosurgery business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Operations
Revenue model
- Medical Device Sales: Apollo Endosurgery generated revenue through sale of endoscopic medical devices including the OverStitch suturing system and Orbera intragastric balloon. OverStitch is a capital/reusable device system while Orbera is a temporary implant with a 6-month placement limit. Revenue derived from hospital and specialty clinic purchases.
- Endoscopic Procedure Products: Revenue from disposable and implantable components used in ESG and TORe procedures. The company provided the full ecosystem of devices needed for endoscopic weight loss procedures.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Medical device pricing for healthcare institutions |
Go-to-market motion1 record
Distribution channels3 records
Marketing channels4 records
Apollo Endosurgery product offering
Product offeringCore offering
Apollo Endosurgery develops and manufactures endoscopic medical devices for minimally invasive weight loss procedures. Its core products include the OverStitch Endoscopic Suturing System (used for Endoscopic Sleeve Gastroplasty and Transoral Outlet Reduction procedures) and the ORBERA Intragastric Balloon System. These devices enable gastroenterologists and bariatric surgeons to perform non-surgical bariatric interventions through the mouth, reducing stomach capacity without external incisions.
Product overview
Apollo Endosurgery, acquired by Boston Scientific in 2024, offers a portfolio of minimally invasive endoscopic bariatric and weight management solutions. The core products include the OverStitch™ Endoscopic Suturing System and OverStitch NXT for performing procedures like Endoscopic Sleeve Gastroplasty (ESG) and Transoral Outlet Reduction (TORe), as well as the ORBERA™ Intragastric Balloon System. These products work together as non-surgical weight loss options performed endoscopically through the mouth, designed to reduce stomach capacity and support healthy lifestyle changes.
Differentiator
Problem solved
Functional benefit
Brands
- OverStitch Endoscopic Suturing System: Endoscopic suturing system for bariatric surgery procedures including ESG and TORe
- ORBERA Intragastric Balloon System
- Endura Weight Loss Solutions
Products and services
- OverStitch Endoscopic Suturing System An endoscopic suturing system for bariatric surgery that reduces stomach size by stitching the inside, indicated for adult patients with obesity (BMI 30-50 kg/m2). Sold to healthcare institutions and specialist physicians.
- OverStitch NXT Endoscopic Suturing System The next-generation version of the OverStitch endoscopic suturing system for bariatric and metabolic procedures, designed for use by trained gastroenterologists and bariatric surgeons in healthcare institutions.
- ORBERA Intragastric Balloon System A temporary intragastric balloon system for weight loss therapy, intended for obese adult patients (BMI 30-40 kg/m2) who have failed to achieve weight loss with supervised programs. Maximum placement time is 6 months. Sold to healthcare institutions.
- Endoscopic Sleeve Gastroplasty (ESG) Procedure A one-time endoscopic procedure that uses internal sutures to reduce stomach capacity by 70-80%, performed using the OverStitch system. Indicated for adult patients with obesity (BMI 30-50 kg/m2).
- Transoral Outlet Reduction (TORe) Procedure A procedure performed using the OverStitch system that retightens the connection between the stomach and small intestine for previous gastric bypass patients who have regained weight, restoring portion control.
Quantifiable outcome
- Patients achieve average 13.6% total body weight loss at year one with ESG procedure combined with diet and exercise counseling
Companies that use Apollo Endosurgery
Customer profileSegments2 records
Ideal customer profiles2 records
Apollo Endosurgery technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Apollo Endosurgery partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Boston ScientificcoreBoston Scientific acquired Apollo Endosurgery for $615 million in April 2023 to strengthen its endoluminal surgery offerings. Apollo Endosurgery became a wholly-owned subsidiary of Boston Scientific. The acquisition provided Boston Scientific with Apollo's portfolio of endoscopic suturing systems (OverStitch) and intragastric balloons (Orbera), and access to Apollo's FDA de novo clearances for endoscopic bariatric systems.
Scale indicators4 records
Recent moves6 records
Expansion highlights5 records
Apollo Endosurgery competitors and assessment
Company assessmentBroad incumbents
- Medtronic: Medtronic is listed alongside Apollo as a key player in automated suturing devices, with a broad surgical portfolio and significant R&D and sales reach to compete in endoscopic bariatric tools.
- Smith & Nephew: Smith & Nephew is listed as a key player in automated suturing devices, with a broader wound closure and sports medicine surgical device portfolio competing in the same OR channel.
- B. Braun: B. Braun is identified as a key competitor in automated suturing devices, with hospital-wide medical device and suture portfolios that overlap with Apollo's target customer base.
- Ethicon (Johnson & Johnson): Ethicon is the dominant surgical suturing franchise inside J&J MedTech and overlaps directly with OverStitch as a broad incumbent in automated and endoscopic suturing.
- Becton, Dickinson and Company (BD): BD is called out among key players in automated suturing, with the Bard hernia and biosurgery franchise; comparable as a broad hospital-channel incumbent competing for the same procedural suturing accounts.
Direct peers
- ReShape Lifesciences: ReShape markets the ReShape and Obalon intragastric balloons and merged with Obalon Therapeutics, making it a directly comparable gastric balloon competitor in the same patient segment.
- Spatz FGIA: Spatz FGIA sells the Spatz3 adjustable intragastric balloon, an FDA-cleared direct rival to Apollo's Orbera in the temporary endoscopic weight loss balloon market.
- Allurion Technologies: Allurion develops the swallowable, balloon-free Elipse gastric balloon for endoscopic weight loss—the most direct head-to-head competitor to Apollo's Orbera intragastric balloon in the non-surgical obesity category.
Emerging players
- USGI Medical: USGI Medical develops incisionless endoscopic suturing and tissue approximation tools (e.g., g-Cath EZ, Incisionless Operating Platform) that overlap with Apollo's OverStitch suturing capabilities in advanced GI procedures.
Others
- Boston Scientific Corporation: Boston Scientific acquired Apollo in 2023 for $615M and now owns and distributes the entire portfolio under the Endura brand—relevant as the parent that controls future commercial and R&D direction.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Apollo Endosurgery social profiles
Digital presenceApollo Endosurgery financial estimates
Financial estimateRevenue estimate
Valuation estimate
Apollo Endosurgery leadership team
Management profileNumber of profiles
Profiles3 records
Apollo Endosurgery funding detail
Funding detailFunding overview
Funding rounds13 records
Investors12 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Apollo Endosurgery M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Apollo Endosurgery
What does Apollo Endosurgery do?
Apollo Endosurgery develops and manufactures endoscopic medical devices for minimally invasive weight loss procedures. Its core products include the OverStitch Endoscopic Suturing System (used for Endoscopic Sleeve Gastroplasty and Transoral Outlet Reduction procedures) and the ORBERA Intragastric Balloon System. These devices enable gastroenterologists and bariatric surgeons to perform non-surgical bariatric interventions through the mouth, reducing stomach capacity without external incisions.
Is Apollo Endosurgery a public or private company?
Apollo Endosurgery is a private company. It is classified as corporate owned and is currently acquired.
When was Apollo Endosurgery founded?
Apollo Endosurgery was founded in 2006. It employs 101 to 250 people.
Where is Apollo Endosurgery based?
Apollo Endosurgery is headquartered in Austin, United States, in the North America region.
How does Apollo Endosurgery make money?
Two revenue lines are on record. Medical Device Sales are the primary driver. The others are endoscopic Procedure Products.
Who are Apollo Endosurgery's main competitors?
Broad incumbents on record are Medtronic, Smith & Nephew, B. Braun, Ethicon (Johnson & Johnson) and Becton, Dickinson and Company (BD). Direct peers are ReShape Lifesciences, Spatz FGIA and Allurion Technologies. USGI Medical is listed as an emerging player. Boston Scientific Corporation is listed as an others.
Does Apollo Endosurgery have an API?
No public API is recorded for Apollo Endosurgery.
What industry is Apollo Endosurgery in?
Apollo Endosurgery's product category is Endoscopic Bariatric Medical Devices. Its primary akta.pro industry code is HLAHADAB, Endoscopy Systems & Accessories (Scopes, Cameras, Light Sources, Insufflation), with a secondary code of HLAHADAN, Endoscopic Therapeutic & Access Devices (Trocars, dilators, biopsy/ablation tools). Its NAICS code is 339112 and its SIC code is 3841.